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Abstract The cost-effectiveness of onabotulinumtoxinA
(BOTOX) 100 U ? best supportive care (BSC) was com-
pared with BSC alone in the management of idiopathic
overactive bladder in adult patients who are not adequately
managed with anticholinergics. BSC included incontinence
pads and, for a proportion of patients, anticholinergics and/or
occasional clean intermittent catheterisation. A five-state
Markov model was used to estimate total costs and outcomes
over a 10-year period. The cohort was based on data from
two placebo-controlled trials and a long-term extension study
of onabotulinumtoxinA. After discontinuation of initial
treatment, a proportion of patients progressed to downstream
sacral nerve stimulation (SNS). Cost and resource use was
estimated from a National Health Service perspective in
England andWales using relevant reference sources for 2012
or 2013. Results showed that onabotulinumtoxinA was
associated with lower costs and greater health benefits than
BSC in the base case, with probabilistic sensitivity analysis
indicating an 89 % probability that the incremental cost-ef-
fectiveness ratio would fall below £20,000. Onabotulinum-
toxinA remained dominant over BSC in all but two scenarios
tested; it was also economically dominant when compared
directly with SNS therapy. In conclusion, onabotulinumtox-
inA appears to be a cost-effective treatment for overactive
bladder compared with BSC alone.
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Incontinence  Cost-effectiveness
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Introduction
Overactive bladder (OAB) is defined by the International
Continence Society as urinary urgency, with or without
urgency incontinence, usually with increased daytime fre-
quency and nocturia, in the absence of other causes of
similar symptoms [1, 2]. OnabotulinumtoxinA (BOTOX,
Allergan, Irvine, CA) is a purified neurotoxin complex for
the treatment of OAB with symptoms of urinary inconti-
nence (UI), urgency and frequency in adults. It is recom-
mended in many clinical guidelines, including those of the
European Association of Urology [3], the American Uro-
logical Association [4] and the UK National Institute for
Health and Care Excellence (NICE) [5], for patients whose
UI symptoms are not managed adequately through beha-
vioural changes or the use of anticholinergic medication.
More than half of patients stop taking anticholinergic agents
because of ineffectiveness, adverse events (AEs), or cost
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[6]. In the absence of onabotulinumtoxinA, patients may
use best supportive care (BSC), including incontinence pads
and, for some individuals, continuation of pharmacological
therapies and occasional use of clean intermittent
catheterisation (CIC), to manage their symptoms, or they
may be candidates for more invasive therapies to manage
OAB such as sacral nerve stimulation (SNS) or surgery [3].
The safety and efficacy of onabotulinumtoxinA in the
management of idiopathic OAB in patients inadequately
managed with anticholinergic medications was assessed in
two double-blind, phase 3 trials (https://clinicaltrials.gov/,
NCT00910520 and NCT00910845) with identical study
designs [7, 8]. In brief, both primary endpoints were met in
the two pivotal trials. At week 12, patients treated with
onabotulinumtoxinA experienced a significantly greater
reduction in UI episodes than those who received a placebo
saline injection (-2.95 vs -1.03 and -2.65 vs -0.87,
respectively; both P\ 0.001), and a significantly greater
proportion reported perceiving an improvement in symp-
toms since receipt of treatment (62.8 vs 26.8 % and 60.8 vs
29.2 %, respectively; both P\ 0.001). Onabotulinumtox-
inA also provided a statistically significant benefit across
secondary endpoints at week 12 compared with placebo,
including urological and health-related quality of life out-
comes. After 12 weeks, all individuals could request
retreatment with onabotulinumtoxinA, and after 24 weeks
patients became eligible to roll over directly into a long-
term extension study (NCT00915525) [9], which will be
completed in 2015.
To support these clinical data, we developed a model to
estimate the cost-effectiveness of onabotulinumtoxinA com-
pared with BSC, as cost-effectiveness data were not available
in this population. A cost-effectiveness model was developed
using pooled data from the phase 3 trials and the long-term
extension trial to estimate the costs and outcomes of the use of
onabotulinumtoxinA ? BSC (hereafter, onabotulinumtox-
inA) compared with BSC alone for the management of idio-
pathic OAB with symptoms of urge UI, urgency and
frequency in adultswhohave an inadequate response to, or are
intolerant of, an anticholinergic medication, over a 10-year
period. The perspective is that of the NHS.
Methods
Model structure
A Markov decision-analytical model was developed to pre-
dict the long-term costs and health outcomes with onabo-
tulinumtoxinA 100 U compared with BSC. The Markov
model was used to simulate transitions between health states
in 3-month model cycles (MC) over a 10-year period
(Fig. 1). Costs and outcomes were estimated for a cohort of
patients who entered the model at the time of the first treat-
ment. A proportion of patients who stopped receiving
onabotulinumtoxinA or BSC could transition to treatment
with SNS (Fig. 2). The health stateswere defined by the daily
number of UI episodes (Fig. 1): 0 episodes (i.e. dry);
[0 to B2 episodes;[2 to\5 episodes; and C5 episodes.
The modelled cohort was based on pooled data from
NCT00910520 and NCT00910845 (n = 1105) and an
interim analysis of the long-term extension trial (n = 825)
conducted after 1 year. These were multinational in design
and included centres in the UK. At baseline, the mean age
was 60.4 years, 87.8 % of participants were women and
the mean [standard deviation (SD)] number of UI episodes
per day was 5.4 (3.6); these patients were considered rep-
resentative of the eligible patient population in the UK. At
baseline and for MC 1, the distribution of patients across
health states observed in the trials was applied to the model
(Table 1). BSC data were derived from patients who
received a saline injection in place of onabotulintoxinA;
however, because randomisation was not maintained after
week 12, owing to crossover to onabotulinumtoxinA, no
transition probabilities were applied at MC 2 or beyond and
it was assumed that individuals would remain in the health
state they were in at the end of MC 1 for the duration of the
time horizon modelled. By contrast, patients receiving
onabotulinumtoxinA could transition between any health
state in each MC. Transition probabilities were derived
from the pooled trial data by averaging UI episodes by MC.
For MC 2–4, transitions were calculated for patients who
were randomised to onabotulinumtoxinA and the mean
transition probability was applied to each MC (Online
Resource 6). To extend the time horizon beyond 1 year, an
average of the transition probabilities for MC 2–4 was
applied to each MC from MC 5 onwards; this extrapolation
used data only from patients who remained on onabo-
tulinumtoxinA for at least 12 months (corresponding to
MC 4) (Online Resource 6).
Patients could request retreatment after 12 weeks in the
pivotal trials if they had C2 urgency UI episodes per day.
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Fig. 1 Five-state Markov decision-analytical model. A patient can
transition into an absorbing health state (dead, not shown) from any of
the disability health states. UIE Urinary incontinence episode(s)
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The median time for patients to receive their first retreat-
ment was 26.6 weeks. A total of 66.7 % of onabo-
tulinumtoxinA patients were retreated in the 1st year. The
proportion of patients who received retreatment during
each MC was applied over year 1, averaged across MC
2–4, and applied to MC 5 and onwards. Discontinuation
from onabotulinumtoxinA was modelled using a criterion
that patients with\50 % reduction in UI episodes from
baseline after two consecutive treatments would discon-
tinue treatment in the 1st year. The proportion of patients
remaining in the onabotulinumtoxinA arm at the end of
year 1 was 78.3 %. Thereafter, a discontinuation rate of
1.4 % per MC was used based on a retrospective study that
followed 125 patients with OAB who received onabo-
tulinumtoxinA over a 5-year period [10]. These assump-
tions broadly agree with the results from a small UK study,
in which most discontinuations occurred after the second
administration of onabotulinumtoxinA, with few discon-
tinuations thereafter [11].
Adverse events
The two most common AEs reported in the trials
NCT00910520 and NCT0910845 were urinary tract
infection (UTI; 20.4 and 15.5 % of patients receiving
onabotulinumtoxinA, respectively) and urinary retention
(5.8 and 5.4 % respectively), and these were included in
the model by MC and by treatment arm (Online
Resource 1) [7, 8]. Urinary retention led to CIC in 6.9 %
and 6.1 % of onabotulinumtoxinA-treated patients in each
of the trials, respectively. Rare AEs (B3 %) reported
during the first 12 weeks of NCT00910520 and
NCT0910845, or those considered to be part of a UTI
such as dysuria (5.8 and 12.2 % respectively) and bac-
teriuria (3.6 and 5.0 % respectively), were not input into
the model because they would have insignificant impact
on the model results.
Utilities
The Incontinence Quality of Life (I-QOL) questionnaire
was administered in the pivotal trials to capture the impact
of UI on patients’ lives. Utility values used for the base-
case analysis were derived from EuroQol-5 dimension
(EQ-5D) values, which were calculated from the I-QOL
through application of a pre-existing mapping algorithm
developed from an international sample of 2351 patients
with idiopathic OAB using the EQ-5D UK tariff [12].
OAB patients (inadequate
management with ACh)
BSC
OnabotulinumtoxinADecision node
Chance node
End nodes
Collapsed brancha
BSC
SNS
BSC
OnabotulinumtoxinA
BSC
SNS
BSC
OnabotulinumtoxinA
Fig. 2 Treatment algorithm for individuals with overactive bladder
(OAB) used in the model. aCollapsed form of the BSC decision node
followed by BSC or SNS (leading to SNS or BSC). ACh
anticholinergic therapy, BSC best supportive care, OAB overactive
bladder, SNS sacral nerve stimulation
Table 1 Model inputs
UIE/day OnabotulinumtoxinA ? BSC
(patients in each health state, %)
OnabotulinumtoxinA ? BSC
(patients receiving retreatment, %)
BSC (patients in each health
state, %)
All patients, EQ-5D
score (mean ± SD)
Baseline Model cycle 1? Model cycle 2? Baseline Model cycle 1?
Dry 0.0 28.9 27.3 0.4 8.2 0.915 ± 0.053
[0 to B2 17.8 33.9 42.0 15.7 26.9 0.853 ± 0.070
[2 to\5 35.1 17.6 50.5 34.4 29.4 0.796 ± 0.070
C5 47.1 19.6 47.3 49.5 35.6 0.767 ± 0.067
BSC best supportive care, EQ-5D EuroQol-5 dimension, UIE urinary incontinence episodes, SD standard deviation
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The EQ-5D utilities were incorporated into the model by
health state, so that each state was assigned a utility value
derived from the average of all EQ-5D values for patients
(months 0–12) in the pooled study population (Table 1).
The EQ-5D values were selected for the base-case analysis
in line with the preference of the UK Health Technology
Assessment agencies. In scenario analyses, Short Form-6
dimension (SF-6D) utility values were also estimated from
the Short Form-12 version 2 (SF-12v2) administered in the
trial [13] as well as calculated directly from the I-QOL,
using a preference-based index developed from valuation
of disease-specific health states in a sample of UK adults
(the Incontinence Utility Index [IUI]) [14]. These utility
values are presented in Online Resource 4.
There were no trial data or published values to provide
utility estimates around the use of SNS appropriate for the
health states in this model. To overcome this, patients with
a successful SNS test or implant (defined as C50 %
reduction in UI episodes) were assumed to have the same
utility values as patients who received onabotulinumtoxinA
at MC 1. Among those who did not respond to the SNS test
or implant, the utility associated with the health state
before SNS was applied. Similarly, there were no published
data to inform estimates of disutility associated with AEs.
A 5 % reduction in utility was applied to all patients who
either experienced a UTI or used CIC, and the utility
decrement lasted for 5 days, in line with previous studies
[15, 16]. Applying an additional decrement was considered
a potentially conservative approach because the impact of
AEs might have been captured by the I-QOL. No disutility
was associated with SNS test or implant procedures.
Resource use and cost
The model incorporated costs of treatment, administration,
follow-up and management of AEs, from the NHS per-
spective in England and Wales, using relevant reference
sources for 2012 or 2013. Resource use and costs are
described in Tables 2 and 3, respectively. Onabotulinum-
toxinA was administered in the hospital outpatient setting;
the cost of administration included a prophylactic course of
antibiotics. In the month before retreatment, it was
assumed that 15 % of patients receiving onabotulinum-
toxinA would be prescribed an anticholinergic [17]. Of the
patients who received BSC, 60 % used anticholinergic
therapy continuously. The cost of anticholinergics was
based on a mix of branded and generic medication derived
from UK retail (British Pharmaceutical Index) and hospital
(Hospital Pharmacy Audit) data (unpublished). Patients
receiving either onabotulinumtoxinA or BSC visited their
physician at a frequency determined by the health state,
irrespective of treatment received. These frequencies were
based on a recent international burden of illness study,
which assessed resource use across subgroups of patients
determined by frequency of UI episodes [18]. Both treat-
ment groups used incontinence pads and it was assumed
that all incontinence pads were reimbursed and were used
at a rate of one pad per UI episode, based on expert advice
(Table 3). The cost of managing AEs comprised the costs
of a primary care physician consultation and a 3-day course
of trimethoprim per episode of UTI. The cost of treating
urinary retention was calculated based on the cost of
catheter use for those requiring CIC, taking frequency and
duration of CIC into account based on clinical trial data
from NCT00910520 and NCT0910845 (CIC rates of 6.9 %
and 6.1 %, respectively). No costs were included for uro-
dynamic testing for individuals receiving either onabo-
tulinumtoxinA or BSC because such testing procedures are
standard in this patient population and independent of the
choice of subsequent treatment [3, 5].
The use of SNS was modelled using data from available
guidelines or, failing that, using weighted averages derived
from a literature review. It was assumed that 29.7 % of
patients who stopped or were not successfully managed
with onabotulinumtoxinA or BSC underwent SNS treat-
ment based on findings from the East Midlands Spe-
cialised Commissioning Group (2012), (the only group to
report such data) [19]. Following the NICE guideline for
the management of UI in women (CG171) [5, 20] SNS
was initiated 3 months after discontinuing treatment with
onabotulinumtoxinA or BSC. Patients underwent testing
before receiving an SNS implant, using a one-stage per-
cutaneous nerve evaluation (PNE) comprising a tined lead
and a temporary electrode with an external battery.
Patients with a successful test received a one-stage SNS
modulator implant, comprising an implanted battery con-
nected to the same lead. Two-stage PNE tests and implants
are used less widely and costs for these were therefore not
included [5, 20]. Temporary PNE electrodes were
removed in all patients who did not respond in the testing
phase (based on NICE Guidelines) [5, 20]. It was assumed
that 7 % of patients who did not respond to SNS would
have the device explanted [21–26], and that among those
who did respond, 23 % would undergo surgical revision
[21, 23–27]. It was assumed that individuals would have
three physician visits for SNS device programming per
year [28]. The SNS batteries were replaced approximately
every 7 years [5].
In one scenario analysis, the cost-effectiveness of SNS
was compared directly with that of onabotulinumtoxinA. In
the absence of randomised head-to-head trial data, this
scenario used the same methodology previously applied to
model SNS as a downstream treatment option. The distri-
bution across health states of patients undergoing SNS after
successful implantation was based on the equivalent dis-
tribution of the onabotulinumtoxinA cohort.
914 N. Freemantle et al.
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Economic analysis
To estimate costs and benefits over the time frame of the
model, the number of patients in each health state at each
cycle was multiplied by costs and utilities associated with
the relevant health state. A 3.5 % annual discount rate was
applied to both costs and benefits [29]. The incremental
cost per quality-adjusted life-year (QALY) gained [the
incremental cost-effectiveness ratio (ICER)] was
calculated.
Pre-specified scenario analyses were used to examine
the impact of changes to key assumptions: reducing the
time frame of the analysis to 3 or 5 years; varying the
discount rate to 0 % or 6 %; considering a female-only
population; using SF-12 and I-QOL IUI to estimate utili-
ties; using the number of UI episodes at baseline for
patients given placebo saline injections to model BSC;
removing anticholinergic use; increasing the cost of
administration; and including SNS as a direct comparator
of onabotulinumtoxinA. Deterministic sensitivity analysis
was used to explore uncertainty concerning individual
input values to the model, with model parameters varied
over a plausible range determined by the standard error or,
if this was not available, by ± 10 % of the point estimate.
In addition, utility values, number of UI episodes and
frequency of follow-up visits were tested by multi-way
analysis such that values were changed simultaneously
across health states to derive total minimum and maximum
ICERs. Parameters with the greatest effect on the ICER
(i.e. those that changed the ICER by more than 10 %) were
included in the tornado diagram (Fig. 3). In addition,
probabilistic sensitivity analyses were used to assess the
overall level of uncertainty in the model via repeated
sampling from each parameter’s distribution using the
Monte Carlo method [30] (Online Resources 2 and 3 for
distributions and ranges).
Results
Base case
In the base-case analysis, onabotulinumtoxinA was asso-
ciated with greater benefit and lower cost than BSC, and
was therefore the economically dominant treatment option
(Table 4). The total discounted cost per patient over the
10-year period was £10,160 with onabotulinumtoxinA and
£11,572 with BSC. Total QALYs were 6.908 with
Table 2 Resource use inputs for the Markov model
Parameter Input Reference
Anticholinergic use as part of BSC (proportion of patients).
Anticholinergic use before onabotulinumtoxinA ? BSC retreatment
(proportion of patients)
60 % Assumption based on clinical opinion
15 % Assumption from the literature [17]
Duration of anticholinergic use before onabotulinumtoxinA ? BSC
retreatment
1 month Assumption from the literature [17]
Number of incontinence pads per UI episode 1 pad Assumption
Proportion of patients who have pads reimbursed 100 % Assumption
Physician visits for patients treated with onabotulinumtoxinA or BSC per month by health state (mean ± SD)
Dry 0.20 ± 0.02 Cost of disease study [18]
[0 to B2 UIE/day 0.30 ± 0.03
[2 to\5 UIE/day 0.38 ± 0.04
C5 UIE/day 0.60 ± 0.06
Proportion of patients undergoing SNS treatment after discontinuing
onabotulinumtoxinA ? BSC or BSC
29.7 % East Midlands Specialised Commissioning
Group [19]. Weighted average calculated
from literature review [21–26]. Weighted
average calculated from literature review
[21–26]
Proportion of patients with a successful SNS test 51.1 %
Proportion of patients with a successful implant 69.2 %
Time to initiation of SNS 3 months Assumption based on NICE CG171 [20]
Proportion of SNS patients with removed temporary PNE electrodes 100 % NICE CG171 and expert opinion [20]
Proportion of SNS patients with explanted device 7.1 % Weighted average calculated from literature
review [21–26]. Weighted average
calculated from literature review [21–27]
Proportion of patients with successful SNS undergoing surgical
revision
23.3 %
Additional physician visits associated with device programming
(per year)
3 NHS England [28]
BSC best supportive care, CG clinical guideline, NHS National Health Service, NICE National Institute for Health and Care Excellence, PNE
percutaneous nerve evaluation, SNS sacral nerve stimulation, UI urinary incontinence, UIE urinary incontinence episodes
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onabotulinumtoxinA and 6.695 with BSC. The main cost
savings with onabotulinumtoxinA were from less down-
stream SNS therapy (-£2188), fewer incontinence pads
(-£1214) and fewer physician visits (-£858) than with
BSC (Online Resource 5).
Sensitivity analyses
Probabilistic sensitivity analysis from sampling the base-
case parameter distributions suggested that there was an
89 % likelihood that the ICER was below £20,000. The
shape of the cost-effectiveness acceptability curve was
relatively flat around the £20,000 willingness-to-pay
threshold, indicating that the probability of onabo-
tulinumtoxinA being cost-effective remains reasonably
consistent around this threshold (Fig. 4, scatter plot shown
in Online Resource 7).
OnabotulinumtoxinA remained dominant over BSC
across most scenarios tested (Table 5). Changing the utilities
did not qualitatively affect the results; however, the QALY
gain with onabotulinumtoxinA compared with BSC was
somewhat smaller using utilities derived from the SF-12
instrument (0.130) and larger using the IUI (0.569) compared
with the EQ-5D utilities used in the base case (0.213).
OnabotulinumtoxinA was also found to be economically
dominant when compared directly with SNS therapy (in-
cremental cost: -£6668; incremental QALYs gained: 0.144)
and when a female-only population was considered. There
were two non-dominant scenarios: when SNS was not
included as a downstream treatment (the ICER was £2369)
and when the cost of onabotulinumtoxinA administration
was increased to £449 (the ICER was £3310).
The tornado diagram (Fig. 3) indicated that the ICER
was most sensitive to the frequency of UTIs. Increasing the
estimated frequency of UTIs from 0 to 2.65 events per
patient per 3-month cycle in the onabotulinumtoxinA arm
led to an ICER of £4133/QALY. The ICER was also
sensitive to the daily number of UI episodes.
Table 3 Cost inputs for the Markov model
Parameter Input
(£)
Reference
OnabotulinumtoxinA (100 U vial) 138.20 BNF [46]
Anticholinergics (per patient per
month)
28.31 Average monthly cost based on market share of generic and branded anticholinergics,
Allergan [data on file] and BNF [46]
Antibiotics (per course) 0.59 BNFa [46]
Incontinence pads (per pad) 0.25 NHS supply chain
Catheters for CIC (per catheter) 0.75 NHS supply chain
OnabotulinumtoxinA administrationb 219.00 HRG tariff LB17Z code for hospital outpatient [47]
Specialist physician visit 102.00 National Schedule of Reference Costs [48]
Physician visit to treat UTI 63.00 Unit costs of health and social care, PSSRU [49]
Removal of temporary SNS electrodes 1166.00 Estimate from NICE CG171: nurse-led visit (£70—non-consultant-led face-to-face
outpatient—PSSRU 2011); explants procedure (£1096, HRG code AA21Z—but may be
less because this is a small procedure) [20]
PNE test (one-stage test) 1485.00 Estimate from NICE CG171. Costs based on estimate from NICE CG171: implantation
(£2441, HRG code AB01Z, complex neurological pain procedure); patient controlled
programmer (£500, NHS, checked by Medtronic, 2012); implantable pulse generator
(£5700, NHS, checked by Medtronic, 2012) [20]
One-stage SNS implant (electrode and
modulator implants)
8641.00
SNS device explant 923.00 OPCS-4 code (A70.2 Removal of neurostimulator in peripheral nerve) [20, 50]. Maintenance
of neurostimulator. Day case/elective inpatient HRG tariff: AB04Z major pain procedures
A70.2 maintenance of neurostimulator in peripheral nerve [20, 47]
SNS surgical revision 592.00
SNS battery replacement 6623.00 Based on estimate from NICE CG171: device (£5700—NICE CG171 does not provide
further information); replacement (£923—HRG A70.2 maintenance of neurostimulator in
peripheral nerve) [20]
SNS follow-up physician visit 319.00 Neurosurgical consultation WF01B OP Code 150 First Attendance–Single Professional [51]
BNF British National Formulary, CG clinical guideline, CIC clean intermittent catheterisation, HRG Healthcare Resource Group, NHS National
Health Service, NICE National Institute for Health and Care Excellence, OPCS-4 Office of Population, Censuses and Surveys Classification of
Surgical Operations and Procedures (4th revision), PNE percutaneous nerve evaluation, PSSRU Personal Social Services Research Unit, SNS
sacral nerve stimulation, UTI urinary tract infection
a UTI per-patient per-episode medication costs BNF 64, trimethoprim 200 mg twice daily (adults) = (82/14 p) 9 2 = 11.71 p/day 9
5 days = 58.57 p
b LB17Z is the introduction of therapeutic substance into the bladder, as admitted care or outpatient procedure. This includes prophylactic use of
antibiotics before the intervention
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Discussion
The cost-effectiveness model showed that, in the base-case
deterministic analysis, onabotulinumtoxinA 100 U was
economically dominant over BSC for the management of
OAB with symptoms of urge UI, urgency and frequency in
adults who have an inadequate response to, or are intol-
erant of, an anticholinergic medication. Economic domi-
nance was achieved through the higher probability of
experiencing a reduction in the number of UI episodes with
onabotulinumtoxinA than with BSC. Reduction in the
frequency of UI episodes was associated with decreased
healthcare resource utilisation, particularly the use of
incontinence pads, and with lower overall costs and
increased quality of life. When uncertainty was taken into
account via a probabilistic sensitivity analysis, there was an
89 % probability that the ICER was below £20,000—a
commonly accepted threshold for cost-effectiveness in the
UK for non-cancer treatments [31]. The relatively flat
curve for the probabilistic analysis around the £20,000
willingness-to-pay threshold indicates a consistent proba-
bility of therapy being cost-effective around this threshold.
Although there is a previously published economic evalu-
ation of onabotulinumtoxinA 100 U for the treatment of
idiopathic OAB [32], this is the first study that incorporates
phase 3 data in line with the newly approved indication
[33].
The model was based on the pivotal trials of onabo-
tulinumtoxinA in OAB [7, 8]. Although the model fol-
lowed the clinical trials as closely as possible, some
modifications were made to incorporate practical aspects of
treating patients with OAB that were not part of the trial
UTI events per patient cycle (onabotulinumtoxinA)
UI episodes per day
UTI events per patient cycle (BSC)
Retreatment (0 or 1 retreatment for non-responders)
Proportion of patients receiving SNS
Cost of administration 
Utility source
Proportion of patients with reimbursed pads
Utility values
Proportion of patients with successful SNS test
Proportion of patients using anticholinergics
Cost of anticholinergics
Cost of onabotulinumtoxinA
Number of incontinence pads per UI episode
Cost of incontinence pad
Cost of SNS implant
UTI events in cycles 2–4 (onabotulinumtoxinA)
Cost of medical care to treat UTIs
Cost of treatment follow-up and incontinence care
Cost of physician follow-up visits
Duration of catheterization in cycle 5 +
Number of CICs in cycle 5 +
Cost of battery replacement
Proportion of patients with successful SNS procedure
–11,000 –9000 –7000 –3000 –1000 3000 5000
ICER base case: –£6635
–5000 1000
 4133
 –2894
 –5025
 –3782
 –6388
 –5526
 –5595
 –5676
 –5619
 –5696
 –5730
 –5776
 –5640
 –5461
 –6034
 –6105
 –6124
 –6027
 –6246
 –6275
 –6276
 –3859
 –6635
 –5036
–10,268
 –9518
 –8137
 –6635
 –8746
 –7787
 –7639
 –7663
 –7583
 –7574
 –7605
 –7556
 –6919
 –6635
 –7196
 –7165
 –7183
 –7006
 –7006
 –7020
 –6977
 –9372
 –10,768
 –8369
Fig. 3 Outcomes of the one-way sensitivity analysis, showing the
effect of changing individual parameters on the ICER (10-year time
horizon). BSC best supportive care, CIC clean intermittent
catheterisation, ICER incremental cost-effectiveness ratio, SNS
sacral nerve stimulation, UI urinary incontinence, UTI urinary tract
infection
Table 4 Results for the base-case analysis for costs and effects discounted at 3.5 % over the 10-year time horizon
Treatment group Total costs (£) QALYs Incremental cost Incremental QALYs ICER
Deterministic OnabotulinumtoxinA 10,160 6.908 -£1412 0.213 Dominant
BSC 11,572 6.695
Probabilistic OnabotulinumtoxinA 10,244 6.838 -£1341 0.152 Dominant
BSC 11,585 6.687
BSC best supportive care, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year
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design, including the use of anticholinergic medication. In
the trials, patients were not able to use anticholinergic
medications, but in clinical practice patients often continue
using anticholinergics as part of BSC, despite the symp-
toms of OAB being inadequately managed with these
drugs. The reduction in OAB symptoms experienced
among individuals randomised to placebo saline injections
was included in the model as a proxy for any potential
efficacy for anticholinergics. This was modelled conser-
vatively as the effect at MC 1 was assumed to last for the
duration of the model (with no further transition proba-
bilities applied in the BSC group).
A key area of uncertainty in cost-utility models is the
source of utility estimates. Valuing states of health for
economic evaluation has often been accomplished using
generic preference-based instruments such as the EQ-5D,
SF-6D and others. However, these instruments may pro-
duce substantially different values for the same health
states, and their ability to discriminate between individuals
whose health states are known to differ and to detect a
known change in an individual’s health state may be lim-
ited [34–38]. Deriving a condition-specific preference
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Fig. 4 Probabilistic sensitivity analysis of onabotulinumtox-
inA ? BSC vs BSC alone for the treatment of OAB using an NHS
perspective in England and Wales. BSC best supportive care, NHS
National Health Service, OAB overactive bladder
Table 5 Results from the scenario analyses
Scenario Treatment Total Incremental
Cost (£) QALYs Cost (£) QALYs ICER
3-year time horizon OnabotulinumtoxinA 3801 2.415 -1442 0.086 Dominant
BSC 5243 2.329
5-year time horizon OnabotulinumtoxinA 5860 3.856 -1243 0.133 Dominant
BSC 7103 3.724
Discount rate: 0 % (costs and effects) OnabotulinumtoxinA 11,702 7.997 -1426 0.243 Dominant
BSC 13,128 7.755
Discount rate: 6 % (costs and effects) OnabotulinumtoxinA 9266 6.276 -1406 0.195 Dominant
BSC 10,671 6.081
No downstream SNS OnabotulinumtoxinA 9910 6.906 565 0.239 £2369
BSC 9344 6.667
Female-only population OnabotulinumtoxinA 10,455 6.979 -1428 0.229 Dominant
BSC 11,883 6.751
SF-12 utilities OnabotulinumtoxinA 10,160 5.683 -1412 0.130 Dominant
BSC 11,572 5.553
I-QOL utilities OnabotulinumtoxinA 10,160 3.105 -1412 0.569 Dominant
BSC 11,572 2.536
BSC, UI episodes at baseline throughout OnabotulinumtoxinA 10,397 6.855 -911 0.305 Dominant
BSC 11,308 6.550
Removal of concomitant anticholinergic use OnabotulinumtoxinA 9941 6.908 -125 0.213 Dominant
BSC 10,066 6.695
Increased cost of onabotulinumtoxinA administrationa OnabotulinumtoxinA 12,276 6.908 704 0.213 £3310
BSC 11,572 6.695
Direct comparison with SNS OnabotulinumtoxinA 10,160 6.908 -6668 0.144 Dominant
SNS 16,828 6.764
BSC best supportive care, ICER incremental cost-effectiveness ratio, I-QOL Incontinence Quality of Life, QALY quality-adjusted life-year, SF-12
Short Form-12, SNS sacral nerve stimulation, UI urinary incontinence
a Cost of administration increased to £449, from tariff LB14E (bladder intermediate endoscopic procedure 19 years and over, 2012–2013 tariff,
admitted care and outpatient procedures)
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index de novo or from an existing condition-specific health
measure is one approach to address these limitations.
Because of this uncertainty, three different utility sources
were used to test the robustness of results in the model. EQ-
5D index values were used in the base case [38]. The
estimated EQ-5D utility difference of 0.15 (0.92–0.77)
between the dry health state and the C5 UI episodes per
day health state is consistent with previous evidence,
including the NICE guideline for UI in women [utility
difference of 0.11 (0.85–0.74)] [5] as well as with earlier
economic evaluations in OAB [15, 32]. Utilities were also
estimated directly from the condition-specific I-QOL [39]
as well as from the SF-12v2 (IUI and SF-6D utilities) [13,
14], and evaluated in scenario analysis. Utilities directly
elicited from the I-QOL tool gave the largest QALY dif-
ferential in favour of onabotulinumtoxinA (0.57), with
utilities from the generic SF-12 giving the smallest dif-
ference (0.13). The QALY differential with the EQ-5D
utilities (0.21) was closer to the SF-12v2 estimate than to
the I-QOL estimate. Despite the variability seen across
utility sources, cost-effectiveness results remained consis-
tent and across each utility source tested, onabotulinum-
toxinA remained dominant over BSC.
Scenario analysis was used to assess the cost-effective-
ness of onabotulinumtoxinA when compared directly with
SNS. This scenario was included as it is potentially rele-
vant in some referral centres in England, in which a deci-
sion is made between treatment with SNS and
onabotulinumtoxinA. In the current analysis, onabo-
tulinumtoxinA was dominant over SNS. This broadly
agrees with the recent NICE analysis, in which the strategy
of providing onabotulinumtoxinA to eligible women was
more likely to be cost-effective, at the £20,000 threshold,
than the strategy of providing SNS first [20].
For two scenario analyses, onabotulinumtoxinA was no
longer dominant over BSC. The first was when SNS was
not included as a downstream treatment. In the base case, a
larger proportion of patients treated with BSC than those
treated with onabotulinumtoxinA did not achieve an ade-
quate response to therapy and were therefore eligible to
receive SNS therapy. Removal of SNS from the treatment
pathway eliminated the associated downstream costs,
which resulted in greater savings in the BSC group. This
led to a non-dominant but still cost-effective ICER in
favour of onabotulinumtoxinA. Although this analysis
shows that the inclusion of SNS makes no qualitative dif-
ference to the finding that onabotulinumtoxinA is a cost-
effective therapy in this indication, SNS is a viable treat-
ment option after failure of initial therapies and it is
therefore warranted to include it somewhere in the treat-
ment pathway.
The second non-dominant scenario resulted when the
administration cost of onabotulintoxinA was increased
(doubled) from £219 to £449 to account for any variation in
tariff used in the NHS [20]. However, the ICER remained
cost-effective even after this increase in cost. The tornado
diagram showed that the model was also sensitive to the
incidence of UTI in the onabotulinumtoxinA arm, and to
the number of UI episodes.
One limitation of the model is that costs and health
outcomes arising from the long-term consequences of
poorly managed OAB and UI were not included. These
might include damage to the skin from prolonged contact
with urine [40, 41], possible fractures and injuries from
falls [42, 43], and increased mortality associated with OAB
in elderly patients [44]. If these data become available,
they could be incorporated into an updated model. A sec-
ond limitation is that the results from some investigator-led
onabotulinumtoxinA studies, with follow-up of up to
8 years, could not be included in the analysis [17].
Although discontinuation rates were modelled using a
retrospective analysis with a median follow-up of
38 months [10], other studies were not included because of
differences in study design (e.g. different dose of onabo-
tulinumtoxinA, non-randomised study design and a dif-
ferent patient population) that would prevent meaningful
comparison with the clinical trial data. The current model
used long-term data from the second interim analysis of the
ongoing long-term extension study (cut-off date 15 May
2012). A third limitation is that the model does not include
treatment with the new oral pharmacological agent mir-
abegron. This was not included as mirabegron was unli-
censed when the model was being developed and did not
have an established clinical profile. A fourth limitation is
that, as with any RCT, the pivotal trials from which the
model data were derived were designed to have the internal
validity required to establish efficacy and safety, but may
not have the external validity needed to demonstrate ‘‘real
world’’ effectiveness. In order to mitigate this limitation,
we used interim efficacy data from the open-label, long-
term extension study in our model [9]. In addition, real-
world studies have corroborated the efficacy and safety
results observed in the pivotal trials [45].
This economic evaluation is expected to be generalis-
able to other healthcare systems. Although this economic
evaluation used costs and resource use specific to England
and Wales, and costs differ substantially across countries,
the overall model structure is in accordance with interna-
tional OAB treatment guidelines [3, 4, 20].
In summary, this study has demonstrated that onabo-
tulinumtoxinA is cost-effective compared with both BSC
and SNS for the treatment of OAB in patients who were not
managed adequately with anticholinergic medication.
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